• Revenue Cycle Management
  • COVID-19
  • Reimbursement
  • Diabetes Awareness Month
  • Risk Management
  • Patient Retention
  • Staffing
  • Medical Economics® 100th Anniversary
  • Coding and documentation
  • Business of Endocrinology
  • Telehealth
  • Physicians Financial News
  • Cybersecurity
  • Cardiovascular Clinical Consult
  • Locum Tenens, brought to you by LocumLife®
  • Weight Management
  • Business of Women's Health
  • Practice Efficiency
  • Finance and Wealth
  • EHRs
  • Remote Patient Monitoring
  • Sponsored Webinars
  • Medical Technology
  • Billing and collections
  • Acute Pain Management
  • Exclusive Content
  • Value-based Care
  • Business of Pediatrics
  • Concierge Medicine 2.0 by Castle Connolly Private Health Partners
  • Practice Growth
  • Concierge Medicine
  • Business of Cardiology
  • Implementing the Topcon Ocular Telehealth Platform
  • Malpractice
  • Influenza
  • Sexual Health
  • Chronic Conditions
  • Technology
  • Legal and Policy
  • Money
  • Opinion
  • Vaccines
  • Practice Management
  • Patient Relations
  • Careers

Health care mergers expected to increase this year

Article

Larger payers will look for “adjacencies” rather than merger and acquisition with other payers because of the regulatory environment.

Last year was a tepid year for merger and acquisition (M&A) deals in the healthcare sector till the fourth quarter according to 2023 Bain Global M&A report. But two large deals in the fourth quarter may be indication that dealmaking will pick up this year, according to the Bain report, which covered other industries besides healthcare

The report notes that many health care companies have large amounts of cash on hand. Pharma company may have a particularly strong appetite for deals because the patents are expiring on many of their top-selling drugs. “That will pressure companies to innovate more quickly and could spark a possible increase in the number of pharmaceutical companies acquiring to catch up on R&D that was stalled during the early days of the pandemic,” says the Bain report, which was released yesterday

The two fourth quarter “megadeals” that the report says may signal that 2023 will see more M&A activity than 2022 were Johnson & Johnson’s $16 billion acquisition of Abiomed, which develops cardiopulmonary devices, and Amgen’s $28 billion acquisition of Horizon Therapeutics, which develops drugs that treat rare diseases. The report’s authors say they expect to deal activity in the pharmaceutical and biotech branch of healthcare to pick up “once companies become comfortable with the macroeconomic uncertainty.” The Inflation Reduction Act will not, says the Bain report, “cause substantial headwinds for dealmaking in 2023.”

The top 25 companies in the payer sector of healthcare have a total of $200 billion on their balance sheets that might encourage dealmaking. But the report also notes that the “current regulatory environment makes the merger of two similar payers challenging in the U.S.” Instead, payers may look for acquisition in “adjacencies.” The report says, though, “it can be hard for large U.S. payers to find big adjacencies that both fit their strategy and will pass regulatory scrutiny.”

The Bain experts said in the report that there were no large provider network acquisitions last year and also referenced the “highly fragmented nature of this space.” The report points to Amazon’s acquisition of One Medical and CVS’ acquisition of Signify Health as evidence of the “continued blurring of the lines between retail and healthcare.”

Related Videos
Monica Verduzco-Gutierrez, MD, FAAPMR, gives expert advice
Claire Ernst, JD, gives expert advice
stock market